Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Mevastatin promotes healing by targeting caveolin-1 to restore EGFR signaling
Andrew P. Sawaya, … , Robert S. Kirsner, Marjana Tomic-Canic
Andrew P. Sawaya, … , Robert S. Kirsner, Marjana Tomic-Canic
Published October 29, 2019
Citation Information: JCI Insight. 2019;4(23):e129320. https://doi.org/10.1172/jci.insight.129320.
View: Text | PDF
Research Article Dermatology Therapeutics

Mevastatin promotes healing by targeting caveolin-1 to restore EGFR signaling

  • Text
  • PDF
Abstract

Diabetic foot ulcers (DFUs) are a life-threatening disease that often results in lower limb amputations and a shortened life span. Current treatment options are limited and often not efficacious, raising the need for new therapies. To investigate the therapeutic potential of topical statins to restore healing in patients with DFUs, we performed next-generation sequencing on mevastatin-treated primary human keratinocytes. We found that mevastatin activated and modulated the EGF signaling to trigger an antiproliferative and promigratory phenotype, suggesting that statins may shift DFUs from a hyperproliferative phenotype to a promigratory phenotype in order to stimulate healing. Furthermore, mevastatin induced a migratory phenotype in primary human keratinocytes through EGF-mediated activation of Rac1, resulting in actin cytoskeletal reorganization and lamellipodia formation. Interestingly, the EGF receptor is downregulated in tissue biopsies from patients with DFUs. Mevastatin restored EGF signaling in DFUs through disruption of caveolae to promote keratinocyte migration, which was confirmed by caveolin-1 (Cav1) overexpression studies. We conclude that topical statins may have considerable therapeutic potential as a treatment option for patients with DFUs and offer an effective treatment for chronic wounds that can be rapidly translated to clinical use.

Authors

Andrew P. Sawaya, Ivan Jozic, Rivka C. Stone, Irena Pastar, Andjela N. Egger, Olivera Stojadinovic, George D. Glinos, Robert S. Kirsner, Marjana Tomic-Canic

×

Figure 1

Mevastatin modulates EGF signaling pathway in primary human keratinocytes to inhibit cell proliferation while promoting EGF-induced cell migration.

Options: View larger image (or click on image) Download as PowerPoint
Mevastatin modulates EGF signaling pathway in primary human keratinocyte...
(A) Heatmap of genes regulated by mevastatin in human primary keratinocytes. (B) Gene ontology analysis of biological processes enriched in mevastatin-treated keratinocytes. Diagram of RNA-Seq data showing mevastatin modulation of EGF signaling pathway by inhibiting cell proliferation while inducing cell migration in human keratinocytes (HEKs). Genes in red indicate mevastatin-induced genes involved in migration and genes in green indicate mevastatin-inhibited genes involved in proliferation. (C) Western blot and quantification of pEGFR (Y1173) and total EGFR and downstream effector pERK and total ERK in HEKs treated with 5 μM mevastatin for 48 hours (n = 6). Mevastatin significantly induced p-EGFR and its downstream effector p-ERK. Data are represented as mean ± SD and were analyzed by Student’s t test; *P < 0.05. (D) Confirmation of RNA-Seq data by qPCR of proliferation and migration genes known to be regulated by EGF signaling in HEKs treated with mevastatin (n = 6). Mevastatin inhibited genes involved in cell proliferation and induced genes involved in migration. Data are represented as mean ± SD and were analyzed by Student’s t test; *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. (E) Western blot and quantification of mevastatin-induced migratory genes (ArhGEF1, Rac2) and proliferation genes (Cyclin B1) suppressed by mevastatin. (F) HEK scratch assay and cell proliferation assay treated in the presence or absence of 25 ng/mL EGF for 24 hours. 50 nM of PD 0332991, a CDK4 inhibitor, served as a control for cell proliferation assay. Mevastatin stimulated keratinocyte migration while inhibiting cell proliferation even in the presence of EGF. Data are represented as mean ± SD and were analyzed by a 1-way ANOVA followed by Holm-Sidak’s post hoc test, **P < 0.01, ***P < 0.001, ****P < 0.0001.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts